C-reactive Protein Predicts Outcome in COVID-19: is It Also a Therapeutic Target?

Overview

Journal Eur Heart J

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2021 Mar 29

PMID 33778886

Citations 21

Authors

Mark B Pepys

Affiliations

Soon will be listed here.

Citing Articles

Pre-hospital oxygen therapy and saturation variability in COVID-19 patients with and without glucose metabolism disorders: part of the COLOS Study.

Bronowicka-Szydelko A, Lewandowski L, Lubieniecki P, Adamiec-Mroczek J, Doroszko A, Trocha M Sci Rep. 2024; 14(1):19286.

PMID: 39164354 PMC: 11335941. DOI: 10.1038/s41598-024-70240-w.

Editorial: Biology of C-reactive protein.

Agrawal A, Wu Y Front Immunol. 2024; 15:1445001.

PMID: 38962011 PMC: 11220225. DOI: 10.3389/fimmu.2024.1445001.

C-reactive protein: structure, function, regulation, and role in clinical diseases.

Zhou H, Tang Y, Xu T, Cheng B Front Immunol. 2024; 15:1425168.

PMID: 38947332 PMC: 11211361. DOI: 10.3389/fimmu.2024.1425168.

Investigation of Serum Endocan Levels in SARS-CoV-2 Patients.

Constantin L, Ungurianu A, Streinu-Cercel A, Sandulescu O, Arama V, Margina D Int J Mol Sci. 2024; 25(5).

PMID: 38474287 PMC: 10932032. DOI: 10.3390/ijms25053042.

Kinetics of IL-6, C-reactive Protein and Fibrinogen Levels in COVID-19 Outpatients Who Evolved to Hypoxemia.

Mendes-Filho S, Pinheiro R, Martins F, Giroldi P, E Melo R, de Oliveira E Clin Pathol. 2024; 17:2632010X231222795.

PMID: 38188270 PMC: 10768631. DOI: 10.1177/2632010X231222795.

References

Vigushin D, Pepys M, Hawkins P . Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993; 91(4):1351-7. PMC: 288106. DOI: 10.1172/JCI116336. View

Pepys M, Gallimore J, Lloyd J, Li Z, Graham D, Taylor G . Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods. 2012; 384(1-2):92-102. PMC: 4068106. DOI: 10.1016/j.jim.2012.07.013. View

Volanakis J, Kaplan M . Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med. 1971; 136(2):612-4. DOI: 10.3181/00379727-136-35323. View

Smilowitz N, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman J . C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021; 42(23):2270-2279. PMC: 7928982. DOI: 10.1093/eurheartj/ehaa1103. View

Liuzzo G, Biasucci L, Gallimore J, Grillo R, Rebuzzi A, Pepys M . The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331(7):417-24. DOI: 10.1056/NEJM199408183310701. View

Gao R, Wang L, Bai T, Zhang Y, Bo H, Shu Y . C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases. EBioMedicine. 2017; 22:133-142. PMC: 5552218. DOI: 10.1016/j.ebiom.2017.07.010. View

ABERNETHY T, Francis T . STUDIES ON THE SOMATIC C POLYSACCHARIDE OF PNEUMOCOCCUS : I. CUTANEOUS AND SEROLOGICAL REACTIONS IN PNEUMONIA. J Exp Med. 2009; 65(1):59-73. PMC: 2133468. DOI: 10.1084/jem.65.1.59. View

Kaptoge S, Di Angelantonio E, Lowe G, Pepys M, Thompson S, Collins R . C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2009; 375(9709):132-40. PMC: 3162187. DOI: 10.1016/S0140-6736(09)61717-7. View

Pepys M, Hirschfield G . C-reactive protein: a critical update. J Clin Invest. 2003; 111(12):1805-12. PMC: 161431. DOI: 10.1172/JCI18921. View

10.

Sheriff A, Schindler R, Vogt B, Abdel-Aty H, Unger J, Bock C . Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?. J Clin Apher. 2014; 30(1):15-21. DOI: 10.1002/jca.21344. View

11.

Siegel J, Rent R, Gewurz H . Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med. 1974; 140(3):631-47. PMC: 2139624. DOI: 10.1084/jem.140.3.631. View

12.

Griselli M, Herbert J, Hutchinson W, Taylor K, Sohail M, Krausz T . C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999; 190(12):1733-40. PMC: 2195725. DOI: 10.1084/jem.190.12.1733. View

13.

Lane T, Wassef N, Poole S, Mistry Y, Lachmann H, Gillmore J . Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res. 2013; 114(4):672-6. DOI: 10.1161/CIRCRESAHA.114.302770. View

14.

Kaplan M, Volanakis J . Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and.... J Immunol. 1974; 112(6):2135-47. View

15.

Szalai A, McCrory M, Xing D, Hage F, Miller A, Oparil S . Inhibiting C-reactive protein for the treatment of cardiovascular disease: promising evidence from rodent models. Mediators Inflamm. 2014; 2014:353614. PMC: 3996300. DOI: 10.1155/2014/353614. View

16.

Pepys M . C-reactive protein fifty years on. Lancet. 1981; 1(8221):653-7. DOI: 10.1016/s0140-6736(81)91565-8. View

17.

Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T . Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342:d548. PMC: 3039696. DOI: 10.1136/bmj.d548. View

18.

Pepys M, Hirschfield G, Tennent G, Gallimore J, Kahan M, Bellotti V . Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440(7088):1217-21. DOI: 10.1038/nature04672. View

19.

ABERNETHY T, AVERY O . THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD : I. DISTRIBUTION OF THE REACTIVE PROTEIN IN PATIENTS' SERA AND THE EFFECT OF CALCIUM ON THE FLOCCULATION REACTION WITH C POLYSACCHARIDE OF PNEUMOCOCCUS. J Exp Med. 2009; 73(2):173-82. PMC: 2135121. DOI: 10.1084/jem.73.2.173. View

20.

Macleod C, AVERY O . THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD : II. ISOLATION AND PROPERTIES OF THE REACTIVE PROTEIN. J Exp Med. 2009; 73(2):183-90. PMC: 2135126. DOI: 10.1084/jem.73.2.183. View